Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry.
Kwai Han YooHyeoung-Joon KimYoo Hong MinDae-Sik HongWon Sik LeeHee-Je KimHo-Jin ShinYong ParkJe-Hwan LeeHawk KimPublished in: PloS one (2021)
Age impacts both the biology and clinical outcomes of AML patients. Further studies should confirm the role of induction remission chemotherapy by age group.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- allogeneic hematopoietic stem cell transplantation
- newly diagnosed
- ejection fraction
- chronic kidney disease
- disease activity
- peritoneal dialysis
- prognostic factors
- electronic health record
- machine learning
- big data
- systemic lupus erythematosus
- acute lymphoblastic leukemia
- locally advanced
- patient reported outcomes
- patient reported